[ET Net News Agency, 2 July 2025] UBS initiates coverage of Hengrui Pharma (01276) with
a target price of HKD76 and a "buy" rating.
The research house said Hengrui Pharma looks well positioned for global expansion with
its comprehensive capabilities and a management team that has deep industry experience.
(rc)